αB-Crystallin Protects Against Cisplatin-Induced Nephrotoxicity by Modulating Apoptosis In Vivo and In Vitro

Area of Science:

• Nephrology
• Molecular Biology
• Biochemistry

Background:

• Cisplatin (CP) chemotherapy causes kidney damage (nephrotoxicity) through tubular epithelial cell apoptosis.
• αB-crystallin (CryAB), a heat shock protein, has known kidney protective roles but its function in CP nephrotoxicity is unclear.
• Understanding CryAB's role is crucial for managing chemotherapy side effects.

Purpose of the Study:

• To investigate the role and molecular mechanisms of αB-crystallin (CryAB) in cisplatin-induced kidney injury.
• To determine if CryAB expression influences renal tubular cell apoptosis and survival pathways.
• To evaluate CryAB as a potential therapeutic target for CP nephrotoxicity.

Main Methods:

• In vitro studies using rat renal tubular epithelial cells (NRK-52E) with CryAB knockdown or overexpression.
• In vivo studies using CryAB knockout and wild-type mice treated with CP.
• Assessment of apoptosis, cell viability, and key signaling pathways (NF-κB, MAPK, AKT).

Main Results:

• CP treatment upregulated CryAB expression and induced apoptosis and MAPK activation in renal cells.
• CryAB deficiency exacerbated CP-induced renal dysfunction, tubular injury, and apoptosis.
• CryAB overexpression attenuated CP-induced kidney damage and apoptosis.
• CryAB modulated NF-κB, MAPK, and AKT signaling pathways, influencing cell survival and apoptosis.

Conclusions:

• αB-crystallin (CryAB) plays a cytoprotective role in cisplatin nephrotoxicity.
• CryAB mitigates tubular apoptosis by influencing mitochondrial pathways and survival signaling.
• CryAB is a potential therapeutic target for reducing chemotherapy-induced kidney injury.